Arrowhead Pharmaceuticals, Inc. SEC filings ARWR
Arrowhead Pharmaceuticals, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Apr 30, 2010. Its latest annual report, Form ARS, was filed on Jan 27, 2026 for the period ended Jan 26, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 4, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (material agreement, new debt). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jan 27, 2026 | — |
| DEF 14A | Proxy statement | Jan 27, 2026 | Jan 26, 2026 |
| DEFA14A | Additional proxy material | Feb 7, 2025 | — |
| DEFA14A | Additional proxy material | Jan 29, 2025 | — |
| DEF 14A | Proxy statement | Jan 29, 2025 | Jan 28, 2025 |
| DEFA14A | Additional proxy material | Feb 27, 2024 | — |
| DEFA14A | Additional proxy material | Jan 26, 2024 | — |
| DEF 14A | Proxy statement | Jan 26, 2024 | Jan 26, 2024 |
| DEF 14A | Proxy statement | Jan 30, 2023 | Jan 30, 2023 |
| PRE 14A | Preliminary proxy statement | Jan 20, 2023 | Mar 16, 2023 |
| DEFA14A | Additional proxy material | Mar 9, 2022 | — |
| DEF 14A | Proxy statement | Jan 26, 2022 | Mar 17, 2022 |
| DEF 14A | Proxy statement | Jan 28, 2021 | Mar 18, 2021 |
| DEF 14A | Proxy statement | Jan 28, 2020 | Mar 19, 2020 |
| PRE 14A | Preliminary proxy statement | Jan 14, 2020 | Mar 19, 2020 |
| DEFA14A | Additional proxy material | Jan 25, 2019 | — |
| DEF 14A | Proxy statement | Jan 25, 2019 | Mar 14, 2019 |
| DEFA14A | Additional proxy material | Jan 25, 2018 | — |
| DEF 14A | Proxy statement | Jan 25, 2018 | Mar 16, 2018 |
| DEFA14A | Additional proxy material | Feb 1, 2017 | — |
| DEF 14A | Proxy statement | Feb 1, 2017 | Mar 21, 2017 |
| DEFA14A | Additional proxy material | Jan 19, 2016 | — |
| DEF 14A | Proxy statement | Jan 19, 2016 | Mar 8, 2016 |
| DEF 14A | Proxy statement | Jan 23, 2015 | Mar 3, 2015 |
| PRE 14A | Preliminary proxy statement | Jan 13, 2015 | Mar 3, 2015 |
| DEF 14A | Proxy statement | Dec 20, 2013 | Feb 6, 2014 |
| DEF 14A | Proxy statement | Feb 4, 2013 | Mar 21, 2013 |
| DEF 14A | Proxy statement | Jan 12, 2012 | Feb 16, 2012 |
| PRE 14A | Preliminary proxy statement | Dec 30, 2011 | Feb 16, 2012 |
| DEF 14A | Proxy statement | Jun 27, 2011 | Aug 8, 2011 |
| PRE 14A | Preliminary proxy statement | Jun 15, 2011 | Aug 8, 2011 |
| DEFA14A | Additional proxy material | Apr 30, 2010 | — |
| DEF 14A | Proxy statement | Apr 30, 2010 | Jun 16, 2010 |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARWR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Pasadena, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 879407
- Former names
- ARROWHEAD RESEARCH CORP (until Apr 6, 2016); INTERACTIVE GROUP INC (until Jan 9, 2004); INTERACTIVE INC (until Feb 13, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.